DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for deafness dystonia syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDeafness dystonia syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for deafness dystonia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2016 report described two patients, mother and daughter, with dystonia-deafness syndrome caused by a p.Arg183Trp mutation in the beta-actin gene, identified after whole-exome sequencing excluded known causes. Bilateral GPi-DBS led to a significant decrease of dystonia and regain of independence in these patients. The same mutation had been reported once before in identical twin brothers with the syndrome. Beta-actin gene mutations are generally associated with developmental Baraitser-Winter syndrome, but the 2016 report noted that dystonia-deafness syndrome can occur with only minimal or no developmental abnormalities of that condition.
A 2018 report described the second known family affected by deafness-dystonia syndrome due to loss of function of FITM2. The patient was compound heterozygous for pathogenic FITM2 variants, while affected siblings in the first report were homozygous. This provided evidence that the disorder is associated with autosomal recessive inheritance. A 2022 table listed characteristics for nine cases diagnosed with dystonia-deafness syndrome related to a beta-actin (ACTB) gene mutation, but no clinical outcomes or treatment responses were given in the available text.
The remaining abstracts are general reviews. A 2004 review summarised efforts to define childhood dystonia, noting that biomechanical, kinematic, and surface EMG measurements show promise for diagnosis and measurement. A 2011 review stated that recognition of dystonia may be underestimated and that proper diagnosis and classification are important for therapeutic decisions. A 2018 book on treatment of dystonia covered botulinum toxin therapy, deep brain stimulation, oral drugs, rehabilitation, and experimental therapies, but gave no specific results for deafness-dystonia syndrome.
What is still missing is any controlled trial of drug therapy for deafness-dystonia syndrome, any systematic comparison of deep brain stimulation targets (GPi versus subthalamic nucleus) in this specific population, and any prospective study with standardised outcome measures. Patient stratification by genotype (ACTB versus FITM2) has not been tested in a treatment trial, and funding for such work is not evident from these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2004 · 39 citations
Toward a definition of childhood dystonia
AbstractPURPOSE OF REVIEW: The purpose of this review is to summarize recent progress toward providing a consistent, sensitive, specific, and useful definition of dystonia as it presents in childhood. RECENT FINDINGS: An NIH-funded consensus group published a definition of childhood dystonia in January of 2003. Recent work has attempted to identify quantitative methods for diagnosis and measurement of childhood dystonia. Techniques include biomechanical, kinematic, and surface EMG measurements that show promise for providing specific and sensitive measures of childhood dystonia. SUMMARY: The results of current research efforts will be useful for verifying and modifying definitions of dystonia to provide consistent and measurable terms for including children in research trials and selecting appropriate interventions for clinical treatment.
Clinical Case Reports · 2018 · 11 citations · open access
The first case of deafness‐dystonia syndrome due to compound heterozygous variants in <i> <scp>FITM</scp> 2 </i>
AbstractKey Clinical Message We report the second known family affected by deafness‐dystonia syndrome associated with loss of function of FITM 2 . Our patient is compound heterozygous for pathogenic FITM 2 variants, while affected siblings in the first report were homozygous. This case provides evidence that this novel genetic disorder is associated with autosomal recessive inheritance.
Cambridge University Press eBooks · 2018 · 10 citations
Treatment of Dystonia
AbstractOur understanding of dystonia is advancing rapidly. This comprehensive reference work provides an effective guide to this challenging group of disorders, offering an overview of the current and emerging treatment options for all manifestations. Treatments for the many forms of dystonia differ substantially in pediatrics and adults - both are covered in detail in this book. Approaches include botulinum toxin therapy, deep brain stimulation, oral drug applications, rehabilitation, and behavioral and experimental therapies. Special emphasis is also given to combining different treatment modalities in order to achieve optimal effect. Treatment of Dystonia brings together peer-reviewed articles, written by experts and based on work presented at international conferences. By enabling the physician to select and combine the best therapies, it is an essential resource for neurologists, neurosurgeons and physical therapists.
Expert Opinion on Medical Diagnostics · 2011 · 3 citations
Diagnostic issues in childhood and adult dystonia
AbstractINTRODUCTION: There is a general agreement among movement disorder specialists that the recognition of dystonia may be underestimated. In parallel, the growing interest and the improving knowledge of genetic and physiopathological aspects of dystonias require systematization. AREAS COVERED: This review focuses on the phenomenology and etiology of pediatric and adult dystonias. It is designed to provide practical help for neurologists and neuropediatricians to make appropriate diagnoses and plan the therapeutical management of these disorders. The reader will get a systematization of the main etiological and diagnostic aspects that differentiate child-onset from adult-onset dystonias. The reader will also gain insights into specific treatments or cures. EXPERT OPINION: Because dystonia can vary in clinical presentation and etiology, proper diagnosis and classification of these disorders are important in making therapeutic decisions.
Case report: Lingual dystonia symptoms treated with botulinum toxin in patients with THAP1 mutation
AbstractBackground: THAP1 mutation dystonia is a known genetic cause of generalized dystonia. THAP1 mutation frequently presents with clinical features of bulbar dysfunction, including oromandibular and lingual dystonia. Patients complain of significant speech, chewing, and swallowing difficulties leading to major occupational and social disabilities. While bilateral globus pallidus internus deep brain stimulation (DBS) is powerful therapy for generalized dystonia and improves dystonia symptoms in the cervical and limb region, it may not improve speech despite multiple adjustments to the stimulation parameters. Treating lingual dystonia symptoms with oral medications is commonly unsatisfactory. Botulinum toxin injection, a potent therapy for focal forms of dystonia is currently underutilized in clinical practice for treating lingual dystonia. Cases: We present two patients with THAP1 mutation reporting lingual dystonia symptoms. The first patient did not meet the eligibility criteria for DBS therapy due to significant psychiatric symptoms. The second patient received DBS with improvements in cervical, limb, and trunk symptoms but complained of severe speech difficulties that did not improve despite multiple programming sessions. These patients were treated with botulinum toxin injections every 12 weeks for more than 3 years, with speech improvements lasting most of the cycle. For the most part they tolerated botulinum toxin without bothersome side effects. Along with the clinical histories, we present objective perceptual analysis of speech samples collected before and after botulinum toxin injections in one of the treatment cycles. Conclusion: Botulinum toxin injections that are clinically beneficial for mitigating lingual dystonia symptoms should be utilized to address symptoms of THAP1 mutation dystonia that may not be amenable to other therapies, such as the DBS.
Movement Disorders Clinical Practice · 2022 · 1 citations · open access
<scp>Dystonia‐Deafness</scp> Syndrome Response to Subthalamic Nucleus Stimulation
AbstractTable S1 Overview of characteristics for 9 cases diagnosed with dystonia-deafness syndrome related to a mutation in the β-actin (ACTB) gene. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Supplementary Material for: Long-Term Follow-Up with Video of a Patient with Deafness-Dystonia Syndrome Treated with DBS-GPi
Abstract<b><i>Background:</i></b> The prevalence of deafness-dystonia syndrome (DDS) is relatively low. To our knowledge, only 2 cases of this syndrome treated with deep brain stimulation (DBS) have been reported. <b><i>Objectives:</i></b> We present a patient with DDS of unknown cause, refractory to medical treatment, who has been successfully treated with DBS of the internal globus pallidus (DBS-GPi) and followed up for 4 years. <b><i>Methods:</i></b> A 21-year-old male, with progressive bilateral sensorineural hearing loss since the age of 3, developed dystonic movements at the age of 12. The patient presented with progressive segmental craniocervical dystonia with jaw-opening, tongue protrusion, retrocollis and gradual overflow including upper limb dystonia. Pharmacological therapy was ineffective. At the age of 17, the patient's condition deteriorated with the risk of developing a dystonic state. <b><i>Results:</i></b> DBS-GPi implantation resulted in a striking improvement. The Burke-Marsden-Fahn Dystonia Rating Scale (BMFDRS) score improved from 75 points before the surgery to 10 points at 3 months after DBS-GPi implantation. Neurological examination at the age of 21 showed mild dystonic movements, mainly oromandibular dystonia (BMFDRS: 15 points). The clinical phenotype of our patient was consistent with Mohr-Tranebjaerg syndrome (MTS). We performed genetic analysis of the <i>TIMM8A</i> gene (the only gene in which mutations are known to cause MTS), but the result was negative; however, other potentially new mutations have to be considered. <b><i>Conclusions:</i></b> Based on our case with the longest reported follow-up of 4 years and 2 earlier reports, we advise to consider DBS-GPi in patients with DDS with unsatisfactory effect of pharmacological treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
